Baker Bros. Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Baker Bros. Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-100,000	Closed	-$766K	–	118
2018 Q2	$766K	Hold	100,000	–	–	0.01%	109
2018 Q1	$2.23M	Hold	100,000	–	–	0.02%	89
2017 Q4	$1.27M	Hold	100,000	–	–	0.01%	105
2017 Q3	$1.56M	Hold	100,000	–	–	0.01%	100
2017 Q2	$1.4M	Hold	100,000	–	–	0.01%	96
2017 Q1	$2.2M	Buy	+100,000	New	+$2.12M	0.02%	85

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baker Bros. Advisors's JNCE Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2018, closing a stake of 100,000 shares — an estimated $766K sold.

Baker Bros. Advisors first reported a position in JNCE in Q1 2017 and held it in 6 quarters. The position peaked at $2.23M in Q1 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q3 2018.

Baker Bros. Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Baker Bros. Advisors sold 100,000 Jounce Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $766K.
Baker Bros. Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 6 quarters.
Baker Bros. Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $2.23M in Q1 2018.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.